Atezolizumab

Atezolizumab is a monoclonal antibody targeting PD-L1, used in the treatment of various cancers including urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, and hepatocellular carcinoma. It works by blocking the interaction between PD-L1 and its receptors, restoring immune system anti-tumor activity. Mediocon Inc supplies pharmaceutical-grade Atezolizumab API for biopharmaceutical manufacturers.

Key Features

• Anti-PD-L1 monoclonal antibody
• IP/BP/EP/USP compliant quality
• Multiple oncology indications
• Immunotherapy checkpoint inhibitor

Applications

• Non-small cell lung cancer treatment
• Urothelial carcinoma therapy
• Triple-negative breast cancer
• Biopharmaceutical manufacturing

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings